Pentagon Abruptly Pulls Mandatory Testosterone Testing Rules Just One Day After Rollout

Pete Hegseth's controversial push to make testosterone screening part of military readiness has hit a startling setback, just one day after the Pentagon released detailed rules for the programme.

On Wednesday, 2 September, the Defence Health Agency published its 'Clinical Guidance for Health and Human Performance Optimisation'. By Thursday, the document and an accompanying statement from Pentagon spokesperson Sean Parnell had disappeared from the Pentagon and Defence Health Agency websites. Clicking the links produced a blunt 'Page Not Found' message.

A US official told Reuters the draft had been 'temporarily rescinded to allow for updates'. Crucially, that does not mean testosterone screening has been cancelled. The interim guidance remains in effect, with final clinical guidance expected shortly.

A Policy That Barely Had Time To Begin

The timing is what makes the reversal so striking. The clinical guidance took effect immediately and established standardised screening and treatment pathways for active-duty and reserve service members aged 30 and older.

For men in that age group, the process included a questionnaire that could lead to mandatory testosterone blood testing and, where medically appropriate, treatment.

Men under 30 were not subject to the same mandatory blood testing, although screening could be requested or recommended when warning signs were present.

In other words, the Pentagon had moved from announcing a controversial policy to publishing detailed clinical instructions, only to pull those instructions roughly 24 hours later.

Hegseth's 'High-T Department of War'

The initiative traces back to July, when Defence Secretary Pete Hegseth announced mandatory testosterone-deficiency screening for service members aged 30 and older.

In a social media video titled 'The High-T Department of War', Hegseth argued that hormone health was part of maintaining the military's physical performance, resilience, and readiness.

He said the initiative was not about artificial enhancement, but about restoring and optimising natural capabilities and maintaining the biological foundation needed to sustain combat operations.

The September guidance marked the point at which that vision became a detailed clinical programme. Then the document vanished.

The Medical Debate Gets Sharper

The controversy is not simply about an administrative document being revised. It goes to the heart of whether widespread testosterone screening can actually improve military readiness.

Neither the American Urological Association nor the Endocrine Society recommends routine screening for low testosterone in asymptomatic men. Medical critics have also questioned whether there is enough evidence that universal screening of service members would improve combat performance.

Dr Jason Goldman, an internal medicine physician and immediate past president of the American College of Physicians, said testosterone replacement can be useful when patients are properly diagnosed, but warned about overtreatment.

He pointed to potential problems including worsened sleep apnoea, increased red blood cell counts, heart risks, infertility, and aggravation of undiagnosed prostate cancer.

Doctors Are Not United

There is, however, another side to the argument. Dr Helen Bernie, an expert in male sexual and reproductive medicine at Indiana University, supports the screening programme because it could identify men with significant underlying health problems.

Bernie also praised safeguards in the withdrawn guidance, including repeat testing, investigation of reversible causes, treatment of those causes, and fertility counselling.

That distinction matters. The debate is not whether testosterone deficiency exists. The question is whether broad screening can identify people who genuinely need treatment without exposing others to unnecessary medical intervention.

Women Were Given a Different Pathway

The guidance also covered female service members, but it did not impose the same mandatory testosterone blood-testing requirement on women.

Instead, women were to undergo clinical screening for symptoms, including fatigue and menstrual irregularities, that could indicate hormonal dysregulation or Relative Energy Deficiency in Sport (RED-S). Further testing and treatment could follow where clinically indicated.

The guidance also addressed testosterone treatment for women in specific circumstances, including Hypoactive Sexual Desire Disorder.

The Story Is Far From Over

For now, the Pentagon pulls testosterone testing rules, but the underlying screening policy remains alive through the interim guidance.

The Pentagon says the detailed clinical document is being updated and that a final version will be issued shortly. Meanwhile, the US Food and Drug Administration is due to convene experts in mid-September to discuss the medical use of testosterone.

That leaves a much bigger question hanging over Hegseth's 'High-T' vision: what will the Pentagon change before the final guidance returns, and how will it balance its readiness ambitions with the medical evidence surrounding testosterone screening and treatment?